NCT/Study#

NCT02616965 /

HM-085

A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients with Requiring Systemic Therapy for Cutaneous T-cell Lymphoma

A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients with Requiring Systemic Therapy for Cutaneous T-cell Lymphoma

DISEASE GROUP:
Lymphoma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: